BONESUPPORT™ to present at Orthopaedic Research Society (ORS) 2018 Annual Meeting
Lund, Sweden, 08.00 CET, 9 March 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces that it will give two oral presentations and a poster presentation at the upcoming Orthopaedic Research Society (ORS) 2018 Annual Meeting. The meeting takes place from March 10-13 at the Hyatt Regency New Orleans in New Orleans, LA and is the leading forum for the presentation of high-quality, innovative and transformative orthopaedic research.
The research to be presented was undertaken by BONESUPPORT™ in collaboration with Lund University in Sweden.
Jerry Chang, Executive Vice President R&D, Regulatory and Clinical, commented:
“We are extremely pleased to be covering important new data via these three presentations at ORS. The data further highlights the benefits of our CERAMENT® platform due to its ability to remodel to host bone, as well as its capability to effectively deliver bone growth factors locally to aid bone formation. This research reaffirms our confidence in the potential of our preclinical pipeline, focused on exploiting the drug eluting properties of CERAMENT® based carriers, in meeting global unmet needs in both fracture repair and prevention.”
The details of the presentations are as follows:
- Paper Title: An Injectable Calcium Sulphate/Hydroxyapatite Biomaterial Delivering rhBMP-2 and ZA for Bone Regeneration in the Femoral Canal of Osteoporotic Rats
Authors: Aurimas Širka, Deepak Bushan Raina, Hanna Isaksson, Elizabeth Tanner, Alfredas Smailys, Šarūnas Tarasevičius, Magnus Tägil, Lars Lidgren
Date & Time: Saturday, March 10, 2018. 3:00 PM - 3:10 PM
Presenter: Aurimas Širka (Orthopaedic Surgeon, combined PhD program at the Lithuanian University of Health Sciences and Lund University, Sweden)
- Paper title: The Effect Of A Biphasic Apatite/Calcium Sulfate Bone Graft Substitute Conjugated With Different Dosages Of Bisphosphonate On Bone Defect Healing In Rats
Authors: Christina Perdikouri, Eva Lidén, Michael Diefenbeck
Date & Time: Tuesday March 13, 2018. 8:14 AM – 8:21 AM
Presenter: Christina Perdikouri (BONESUPPORT R&D Scientist, PhD)
Poster and paper title: In-vitro And In-vivo Carrier Properties Of A Macroporous Composite Biomaterial For Sustained Delivery Of Bone Morphogenic Protein-2 And Zoledronic Acid
Authors: Deepak Raina, David Larsson, Filip Mrkonjic, Hanna Isaksson, Ashok Kumar, Lars Lidgren, Magnus Tägil
The paper will be presented in poster session “Biomaterials – Technologies” and as a 1-minute poster teaser presentation.
Date & Time: Monday March 12, 3:15 PM – 4:15 PM
Presenter: Deepak Raina (Department of Orthopaedics, Medical Faculty, Lund University, Sweden)
Poster Teaser Presentation:
Date & Time: Saturday March 10. Presentation as part of poster teaser session 2:15 PM - 3:20 PM; presentation time: 2:47pm - 2:48pm
Presenter(s): Deepak Raina (Department of Orthopaedics, Medical Faculty, Lund University, Sweden)
For more information contact:
Emil Billbäck, CEO
+46 (0) 286 53 70
Björn Westberg, CFO
+46 (0) 46 286 53 60
Citigate Dewe Rogerson
Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews
+44 (0)20 7282 1022
BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.
BONESUPPORT’s marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary CERAMENT technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.
BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%. The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States
BONESUPPORT™ and CERAMENT® are registered trademarks.